Back

Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles

Mu, Z.; Wiehe, K.; Saunders, K. O.; Henderson, R.; Cain, D. W.; Parks, R.; Martik, D.; Mansouri, K.; Edwards, R. J.; Newman, A.; Lu, X.; Xia, S.-M.; Bonsignori, M.; Montefiori, D.; Han, Q.; Venkatayogi, S.; Evangelous, T.; Wang, Y.; Rountree, W.; Tam, Y.; Barbosa, C.; Alam, S. M.; Williams, W. B.; Pardi, N.; Weissman, D.; Haynes, B. F.

2021-08-09 immunology
10.1101/2021.08.09.455714 bioRxiv
Show abstract

The success of nucleoside-modified mRNAs in lipid nanoparticles (mRNA-LNP) as COVID-19 vaccines heralded a new era of vaccine development. For HIV-1, multivalent envelope (Env) trimer protein nanoparticles are superior immunogens compared to trimers alone for priming of broadly neutralizing antibody (bnAb) B cell lineages. The successful expression of complex multivalent nanoparticle immunogens with mRNAs has not been demonstrated. Here we show that mRNAs can encode antigenic Env trimers on ferritin nanoparticles that initiate bnAb precursor B cell expansion and induce serum autologous tier 2 neutralizing activity in bnAb precursor VH + VL knock-in mice. Next generation sequencing demonstrated acquisition of critical mutations, and monoclonal antibodies that neutralized heterologous HIV-1 isolates were isolated. Thus, mRNA- LNP can encode complex immunogens and are of use in design of germline-targeting and sequential boosting immunogens for HIV-1 vaccine development.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.